Aletinib is a tyrosine kinase inhibitor that works by targeting the activity of anaplastic lymphoma kinase (ALK) and RET.

1、 Drug name

1. Common name: Alectinib

2. Product Name: ALECENSA ® (Anshengsha)

2、 Indications

Used to treat patients with anaplastic lymphoma kinase (ALK) positive, metastatic non-small cell lung cancer (NSCLC) who have progressed or are intolerant to crizotinib treatment.

3、 Specifications and characteristics

Specification: 150mg hard capsule.

4、 Main components

1. Active ingredient: Alectinib

2. Accessories: lactose monohydrate, hydroxypropyl cellulose, sodium dodecyl sulfate, magnesium stearate, carboxymethyl cellulose calcium, etc.

5、 Usage and dosage

1. Recommended dosage: 600mg (4 150mg capsules) orally, twice daily, taken with meals.

2. Omission treatment: If medication is missed or vomiting occurs after taking it, there is no need to take it again, and the next dose should be taken according to the original plan.

6、 Dose adjustment

Adjust the dosage according to the severity of adverse reactions:

1. First dose reduction: 450mg (twice daily).

2. Secondary reduction: 300mg (twice daily).

3. Unable to tolerate 300mg: permanently discontinue medication.

4. The specific adjustment criteria include liver toxicity, bradycardia, elevated creatine kinase, etc.

7、 Medication precautions

1. Dietary requirements: Should be taken with meals to improve bioavailability.

2. Contraindications: There are no clear contraindications, but one should be cautious of serious adverse reactions such as hepatotoxicity and interstitial lung disease.

8、 Medication for special populations

1. Pregnant women: May cause harm to the fetus, contraception is necessary.

2. Breastfeeding period: Avoid breastfeeding within one week after discontinuing medication.

3. Children/elderly: Safety is not clear and needs to be carefully evaluated.

9、 Adverse reactions

1. Common reactions (incidence ≥ 20%): fatigue, constipation, edema, muscle pain.

2. Serious reactions: liver injury (3.6% -4.8%), interstitial lung disease (0.4%), bradycardia (7.5%).

10、 Drug interactions

1. Strong CYP3A inhibitors/inducers: No need to adjust dosage.

2. Antacids: No significant effects were found.

11、 Storage method

1. Temperature: ≤ 30 ° C (86 ° F)

2. Packaging: Original bottle sealed, away from light and moisture.

Alectinibinformation